• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 30, 2018

View Archived Issues

Tonix tonic comes up short in PTSD phase III trial

The lead program at Tonix Pharmaceuticals Holding Corp., a medicine aimed at delivering bedtime relief from symptoms of military-related post-traumatic stress disorder (PTSD), failed to adequately separate from placebo in an interim analysis of 12-week phase III data. News of the setback, the second pivotal miss for the drug, sent company shares (NASDAQ:TNXP) down 65.8 percent to $1.35 on Friday, as Tonix pursued hopes that the FDA might judge a future study by a data cut more favorable to the drug. Read More

Amgen keeps on trucking; turnover in big bio C-suite rolls along, too

"Like clockwork, Amgen just finds a way," Piper Jaffray's Christopher Raymond headlined his hot comment on second-quarter earnings from Amgen Inc. Numbers from the Thousand Oaks, Calif-based company were solid, if not spectacular. Quarterly revenues increased 4 percent, to $6.1 billion, over the second quarter of 2017, and global product sales, which included the company's first biosimilar, Kanjinti, grew 2 percent. Read More

Regulatory actions for July 27, 2018

Read More

Clinical data for July 27, 2018

Read More

Other news to note

Pharmamar SA, of Madrid, said it signed an agreement with Impilo Pharma, a part of Immedica Group, of Stockholm, for the exclusive promotion and distribution of its cancer compound, Yondelis (trabectedin), throughout the Nordic countries and Eastern Europe.  Read More

Financings

Contrafect Corp., of Yonkers, N.Y., said it priced its underwritten public offering of 5 million shares of its common stock at $2 per share for gross proceeds of $10 million. The company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price. Read More

Regulatory front

The FDA issued a draft of guidelines for providing evidence of effectiveness for replacement or corrective therapies in slowly progressive, low-prevalence rare diseases with substrate deposition that results from single-enzyme defects. Among the topics in the 13-page document is first-in-human dosing.  Read More

Bench Press: BioWorld looks at translational medicine

The gene STK11 encodes the tumor suppressor liver kinase B1 (LKB1), and STK11 mutations promote Peutz–Jeghers syndrome (PJS), a cancer predisposition syndrome. Individuals with PJS are prone to developing gastrointestinal polyps, which can lead to gastrointestinal (GI) tumors. Researchers from the Van Andel Research Institute and the Canadian McGill University have shown that STK11 mutations led to increased inflammation, and that targeting the inflammation could improve outcomes in mouse models of PJS.  Read More

Simplifying nanomedicine manufacturing for the masses

It's been more than two decades since Doxil (doxorubicin, Johnson & Johnson), a liposome-based chemotherapy, was approved by the FDA. During that time, the field has evolved from simply protecting other tissue from highly potent drugs until they get to the site of the disease to increasing targeting and bioavailability. Read More

Merck's Keytruda cleared as first anti-PD-1 antibody in China for melanoma

HONG KONG –MSD China Holding Co. Ltd. (known as Merck & Co. Inc. in the U.S. and Canada) received approval for Keytruda (pembrolizumab) in China, making it the second PD-1 inhibitor drug approved in the country after Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and the first one for advanced melanoma. Read More

Sanbio eyeing Japan's aging population with dementia bid for cell therapy SB-623

HONG KONG – Japan's Sanbio Co. Ltd., a maker of regenerative medicines for neurological disorders, is working with Keio University School of Medicine to research its SB-623 drug for the treatment of dementia, including Alzheimer's disease and cerebral vascular dementia. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe